Thrombosis‐Driven Disease Progression in JAK2‐Mutant Polycythemia Vera and Essential Thrombocythemia: Reassessing Risk‐Based Management

Documenti analoghi

• Subtype‐Specific Risk of Non‐Melanoma Skin Cancers in MPN Patients: An Expanded Analysis of the MPN ‐K Case–Control Database
  di: Tiziano Barbui, et al.
  Pubblicazione: (2026)
• Extending the Biological Axis Linking CHIP to Cancer Emergence
  di: Tiziano Barbui, et al.
  Pubblicazione: (2025)
• Triple A Plus ( AAA + ) Survival Prediction Model for Essential Thrombocythemia: Analysis Involving 7308 Patients
  di: Ayalew Tefferi, et al.
  Pubblicazione: (2025)
• A Novel, Ruxolitinib‐Sensitive, CCDC6 :: JAK2 Fusion Gene in a Patient With Atypical, JAK2 Unmutated, Polycythemia Vera‐Like, Myeloproliferative Neoplasm
  di: Niccolò Bartalucci, et al.
  Pubblicazione: (2025)
• A Clinically Applicable Model Using Blood Counts to Support the Diagnosis of Prefibrotic Myelofibrosis Versus Essential Thrombocythemia
  di: Tiziano Barbui, et al.
  Pubblicazione: (2025)